Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct;46(10):1409-1414.
doi: 10.3899/jrheum.181071. Epub 2019 Feb 1.

OMERACT Development of a Core Domain Set of Outcomes for Shared Decision-making Interventions

Affiliations

OMERACT Development of a Core Domain Set of Outcomes for Shared Decision-making Interventions

Karine Toupin-April et al. J Rheumatol. 2019 Oct.

Abstract

Objective: The Outcome Measures in Rheumatology (OMERACT) Shared Decision Making (SDM) Working Group aims to determine the core outcome domain set for measuring the effectiveness of SDM interventions in rheumatology trials.

Methods: A white paper was developed to clarify the draft core domain set. It was then used to prepare for interviews to investigate reasons for lack of consensus on it and to suggest further improvements.

Results: OMERACT scientists/clinicians (n = 13) and patients (n = 10) suggested limiting the core domain set to outcome domains, removing process domains, and clarifying remaining domains.

Conclusion: A revised core domain set will undergo further consensus-building.

Keywords: OMERACT; OUTCOMES; RHEUMATIC DISEASES.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: There are no conflicts of interest.

Figures

FIGURE 1.
FIGURE 1.
DRAFT CORE DOMAIN SET DIVIDED INTO PROCESS AND OUTCOME DOMAINS PRESENTED IN THE WHITE PAPER
FIGURE 2:
FIGURE 2:. REVISED DRAFT CORE OUTCOME DOMAIN SET
Outer circle (research agenda): Outcome domains that domains that require further investigation Middle circle: Outcome domains that are strongly recommended to measure but not mandatory Inner circle: Outcome domains that are mandatory to measure in all clinical trials of SDM interventions Description of the domains: - Knowledge of all options, their potential benefits and risks: The shared decision making intervention helps patients understand the available options and their potential benefits, risks. It also helps them to know the probabilities of benefits and risks in an accurate manner. Knowledge of: 1. All available options (including nothing) 2. Benefits 3. Risk - Choice of an option aligned with each patient’s values/preferences The shared decision making intervention helps patients choose the treatment option that matches their values and preferences. It means they chose the treatment option that has the features that they value most. - Confidence in the decision made (i.e., decisional certainty) The shared decision making intervention helps patients feel sure they made the best decision. It means they feel confident in the decision they made. This is the opposite of decisional conflict (i.e., decisional uncertainty). - Satisfaction with the decision-making process The shared decision making intervention helps patients feel satisfied about the way they made the decision. - Adherence to the chosen option The shared decision making intervention helps patients follow through with the chosen treatment option. It means they start using the option they chose.

References

    1. Chewning B, Bylund CL, Shah B, Arora NK, Gueguen JA, Makoul G. Patient preferences for shared decisions: a systematic review. Patient Educ Couns 2012;86:9–18. - PMC - PubMed
    1. Elwyn G, Tilburt J, Montori V. The ethical imperative for shared decision-making. Eur J Pers Cent Healthc 2013;1:129–31.
    1. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631–7. - PMC - PubMed
    1. Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960–77. - PubMed
    1. Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016;75:499–510. - PubMed

Publication types

LinkOut - more resources